Brief: FDA Accepts Interim Analysis Plan For Ongoing Phase 2b Ibezapolstat Clinical Trial
11/04/2023 12:32
April 11 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* FDA ACCEPTS INTERIM ANALYSIS PLAN FOR ONGOING PHASE 2B
IBEZAPOLSTAT CLINICAL TRIAL AND ACURX ANNOUNCES PRESENTATIONS AT
ECCMID 2023 SCIENTIFIC CONFERENCE
* ACURX PHARMACEUTICALS INC: INTERIM REVIEW WILL BE
CONDUCTED UPON
REACHING ENROLLMENT OF 36 PATIENTS IN TOTAL
* ACURX PHARMACEUTICALS INC: INTENDS TO REPORT AVAILABLE
DATA
PROMPTLY AFTER IDMC CONDUCTS INTERIM REVIEW
* ACURX PHARMACEUTICALS-FDA'S ACCEPTANCE WAS BASED ON CO'S
FILING
OF PROTOCOL AMENDMENT TO ITS INVESTIGATIONAL NEW DRUG
APPLICATION WITH FDA IN JAN 2023
Source text for Eikon: ID:nPn377JWZa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln